Susquehanna Fundamental Investments LLC Buys Shares of 8,745 ANI Pharmaceuticals, Inc. $ANIP

Posted by Stanley Muller on Sep 3rd, 2026

Susquehanna Fundamental Investments LLC purchased a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) in the second quarter, according to its most recent filing with the SEC. The firm purchased 8,745 shares of the specialty pharmaceutical company’s stock, valued at approximately $724,000.

Several other institutional investors have also modified their holdings of ANIP. Arrowstreet Capital Limited Partnership purchased a new position in ANI Pharmaceuticals in the 3rd quarter valued at approximately $32,992,000. Ranger Investment Management L.P. purchased a new stake in ANI Pharmaceuticals during the second quarter worth $28,406,000. Deutsche Bank AG acquired a new stake in ANI Pharmaceuticals in the second quarter valued at $26,775,000. Balyasny Asset Management L.P. grew its holdings in ANI Pharmaceuticals by 2,785.7% in the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after purchasing an additional 276,233 shares during the last quarter. Finally, William Blair Investment Management LLC purchased a new position in shares of ANI Pharmaceuticals in the second quarter valued at $21,372,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 5,400 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $74.30, for a total value of $401,220.00. Following the sale, the chief executive officer owned 344,489 shares in the company, valued at approximately $25,595,532.70. This trade represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 3,313 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total value of $284,918.00. Following the sale, the chief financial officer directly owned 177,543 shares in the company, valued at approximately $15,268,698. This trade represents a 1.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 27,237 shares of company stock worth $2,155,105 in the last quarter. 8.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

ANIP has been the subject of several research reports. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Guggenheim decreased their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Finally, Canaccord Genuity Group lowered their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $105.83.

View Our Latest Stock Analysis on ANI Pharmaceuticals

ANI Pharmaceuticals Stock Performance

ANIP stock opened at $73.06 on Thursday. ANI Pharmaceuticals, Inc. has a 1 year low of $70.15 and a 1 year high of $99.50. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of 15.75 and a beta of 0.45. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The stock’s fifty day moving average is $79.12 and its two-hundred day moving average is $78.53.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last released its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. The business had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company’s quarterly revenue was up 25.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

ANI Pharmaceuticals Company Profile

(Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.